Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EFLN BREAKOUT COMING
.0015s UP NOW .0016 HURRY
EFLN GETTING ASK SLAPPED NEEDS VOLUME .0014
EFLN JUST KEPS GETTING HIT WITH GREEN SHOULD FLY THIS WEEK ALREADY UP ON THE DAY
EFLN SHOULD BE HITTING PENNY NOTHING BUT GREEN
EFLN .0014 ready to ROCK
BREAKOUT COMING
Ask at .0015 sweet
Ready to rock EFLN
I'm in
4 s are here
Blast offf
LETS MAKE SOME MONEYYYYYY GO BMSN
$BMSN FDA APPROVED
I'm in at .008 so I'm stuck I think it will go back up in couple weeks
Jumped on the CCRY Band wagon
Looks like a run coming today
They've sure been doing a good job at it
Nothing
What is the purpose of MICA @ 1000 on the ask?
RAYS GOING BACK DOWN TO .0024 eod
.02 looks like it will show up end of week
Green! That was quick
This stock is MONEYYYYYY
$PMCM HUGE GAINS TODAY EARLY MORNING BID WHACKERS COULD SEE .02+
What is everyone's predictions for the high of the day
Here we goooooooo
Definitely penny land tomorrow
I feel lucky to have grabbed .0040s
$BMSN SHORT SQUEEZE COMING
2100000 t trade
$BMSN HUGE VOLUME NEWS
Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today its submission of responses to the U.S. Food and Drug Administration's (FDA) comments regarding its IND # 15376 covering the use of HemaXellerate for treatment of immune suppressant resistant aplastic anemia. As part of the response to comments, Regen BioPharma provided new data demonstrating efficacy of the HemaXellerate product at accelerating stem cell recovery after chemotherapeutic injury.
"We are pleased with the responses that we have provided to the FDA and look forward to initiating our clinical trials," stated David Koos, Chairman and CEO of Regen BioPharma. "Although it is possible that a second round of comments may be issued, we feel this process is extremely useful to creating a clinical trial that is optimized for safety and detection of efficacy."
The HemaXellerate clinical trial aims to recruit 10 patients with aplastic anemia that have not shown material signs of improvement under the current the standard of care. If successful, the company will progress to larger efficacy-finding trials, as well as expansion to other diseases that would benefit from enhancement of bone marrow stem cells.
The scientific rationale for HemaXellerate, as well as some of the supporting data, may be found in the peer reviewed publication titled "Exogenous endothelial cells as accelerators of hematopoietic reconstitution," which is available at this link http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf
Currently there is a need for therapies that stimulate bone marrow stem cells. HemaXellerate utilizes cells derived from the patient's own fat stem cells to repair and stimulate the hematopoietic stem cells of the bone marrow, which are responsible for production of blood. The current market for therapies that stimulate blood cell production is in the billions of dollars per year. Neupogen and Neulasta, two products that stimulate production of white blood cells had sales of $4.84 Billion in 2010 http://www.wikinvest.com/stock/Amgen.
About Bio-Matrix Scientific Group, Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) through its wholly owned subsidiary, Regen BioPharma, Inc., is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. To follow our development, visit us at www.regenbiopharma.com.
NEWS NEWS
Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today its submission of responses to the U.S. Food and Drug Administration's (FDA) comments regarding its IND # 15376 covering the use of HemaXellerate for treatment of immune suppressant resistant aplastic anemia. As part of the response to comments, Regen BioPharma provided new data demonstrating efficacy of the HemaXellerate product at accelerating stem cell recovery after chemotherapeutic injury.
"We are pleased with the responses that we have provided to the FDA and look forward to initiating our clinical trials," stated David Koos, Chairman and CEO of Regen BioPharma. "Although it is possible that a second round of comments may be issued, we feel this process is extremely useful to creating a clinical trial that is optimized for safety and detection of efficacy."
The HemaXellerate clinical trial aims to recruit 10 patients with aplastic anemia that have not shown material signs of improvement under the current the standard of care. If successful, the company will progress to larger efficacy-finding trials, as well as expansion to other diseases that would benefit from enhancement of bone marrow stem cells.
The scientific rationale for HemaXellerate, as well as some of the supporting data, may be found in the peer reviewed publication titled "Exogenous endothelial cells as accelerators of hematopoietic reconstitution," which is available at this link http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf
Currently there is a need for therapies that stimulate bone marrow stem cells. HemaXellerate utilizes cells derived from the patient's own fat stem cells to repair and stimulate the hematopoietic stem cells of the bone marrow, which are responsible for production of blood. The current market for therapies that stimulate blood cell production is in the billions of dollars per year. Neupogen and Neulasta, two products that stimulate production of white blood cells had sales of $4.84 Billion in 2010 http://www.wikinvest.com/stock/Amgen.
About Bio-Matrix Scientific Group, Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) through its wholly owned subsidiary, Regen BioPharma, Inc., is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. To follow our development, visit us at www.regenbiopharma.com.
Got 400000 at .0026
$EAPH
$ORFG set to take off
Why is everyone selling LOAD UP
Big buys still coming in
Went back up
What's going on with the company now imds let's here something